文献速递认知障碍与痴呆

仑卡奈单抗治疗的相关问题

Lecanemab Questions.
PubMed 文献 · Neurology · 2024-03-14

本文针对仑卡奈单抗18个月随机对照试验的结果提出多项值得进一步考虑的问题,包括盲法成功性未评估、结局指标绝对值未定义、与多奈哌齐的效应比较、治疗负担与获益的时间折扣、以及淀粉样蛋白单抗与脑萎缩的关联,并建议在治疗讨论中提出这些问题。

要点

  • 仑卡奈单抗延缓早期阿尔茨海默病进展的试验未评估盲法成功性,输注反应和ARIA可能提示用药分组,或产生安慰剂效应。
  • 仑卡奈单抗在CDR-SB上的组间差异仅为最小临床重要差异估计值的18%至46%,绝对价值未定义。
  • 18个月时仑卡奈单抗在ADAS-Cog14上的变化衰减为多奈哌齐6个月时效果的50%。

核心结论

  • 仑卡奈单抗试验存在盲法成功性未评估、结局绝对值未定义、治疗负担高且获益延迟、以及淀粉样蛋白单抗与脑萎缩相关等问题,应在与患者治疗讨论中提出。

研究设计与样本

  • 本文为针对已发表的仑卡奈单抗18个月随机对照试验结果的评论文章。

主要发现

  • 盲法成功性未评估,输注反应和淀粉样蛋白相关影像学异常(ARIA)的脑病理可能向许多参与者提示用药分组,或产生强安慰剂效应。
  • 仑卡奈单抗在临床痴呆评定量表总和(CDR-SB)上的组间差异为最小临床重要差异估计值的18%至46%。
  • 18个月时仑卡奈单抗在阿尔茨海默病评估量表-认知14(ADAS-Cog14)上的变化衰减为多奈哌齐6个月时效果的50%。
  • 仑卡奈单抗治疗负担高,负担始于治疗开始而获益在数年后才出现,需考虑价值随时间折扣,将显著降低获益/负担比。
  • 针对脑淀粉样蛋白的单克隆抗体治疗一致与进行性脑萎缩相关。

临床怎么用

  • 作者认为至少应在与患者的治疗讨论中提出上述问题。
  • 作者认为需要非常认真地重新考虑在将临床试验结果转化为临床实践前如何评估这些结果。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The recently published results of the 18-month randomized controlled trial of lecanemab, reporting the efficacy of the drug in slowing the progression of early Alzheimer disease, quickly led to approval by the FDA and widespread acceptance of lecanemab treatment. However, there are a number of matters that deserve further consideration. The success of blinding was not assessed, even as infusion reactions and the cerebral pathology underlying amyloid-related imaging abnormalities could have signaled to many participants that they were on drug, potentially exerting a potent placebo effect. The value of the outcome to participants is not defined in the absolute terms necessary for clinical decision-making, and the difference attributable to lecanemab was between 18% and 46% of estimates of the minimal clinically important difference on the Clinical Dementia Rating Scale Sum of Boxes. The attenuation of change on the Alzheimer's Disease Assessment Scale-Cognitive 14 achieved by lecanemab at 18 months was 50% of that achieved by donepezil at 6 months. Lecanemab treatment imposes a high treatment burden. The fact that the burden commences at the initiation of lecanemab treatment, whereas the benefit accrues years later requires us to take into account value discounting over time, which would significantly reduce the benefit/burden ratio. Finally, treatment with monoclonal antibodies to cerebral amyloid has consistently been associated with progressive cerebral atrophy. At the least, these issues should be raised in treatment discussions with patients. They also suggest a need to very seriously reconsider how we evaluate clinical trial results preparatory to translating them into clinical practice. Some suggestions are provided.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Nadeau SE. Lecanemab Questions. Neurology. 2024. PMID: 38484213. doi:10.1212/WNL.0000000000209320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。